Cardio Diagnostics Holdings Inc. (CDIOW)
Market Closed
10 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 02
0
0%
Pre Market
$
+0 +16.0428% 0. 02
49.7K Market Cap
- P/E Ratio
- Div Yield
3,875 Volume
- Eps
$ 0.02
Previous Close Investors:
Want to track CDIOW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CDIOW closed yesterday higher at $0.02, an increase of 0% from Tuesday's close, completing a monthly increase of 43.8462% or $0.01. Over the past 12 months, CDIOW stock lost -10.9524%.
CDIOW is not paying dividends to its shareholders.
The last earnings report, released on Jun 03, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.9%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Cardio Diagnostics Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 82,442 | $1,681.92 | $1,648.84 | -$33.08 | -1.97% |
Cardio Diagnostics Holdings Inc. (CDIOW) FAQ
What is the stock price today?
The current price is $0.02.
On which exchange is it traded?
Cardio Diagnostics Holdings Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is CDIOW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 49.7K.
Has Cardio Diagnostics Holdings Inc. ever had a stock split?
No, there has never been a stock split.
Cardio Diagnostics Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Meeshanthini V. Dogan CEO | NASDAQ (CM) Exchange | 14159C111 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Cardio Diagnostics Holdings, Inc. is a pioneering enterprise situated in Chicago, Illinois, dedicated to the development and commercialization of cutting-edge epigenetics-based clinical tests specifically designed for cardiovascular diseases. Since its inception in 2017, the company has been at the forefront of leveraging epigenetic technologies to enhance the diagnosis and risk assessment of coronary heart disease (CHD), aiming to significantly improve patient outcomes through earlier detection and personalized treatment strategies.
Products and Services
Cardio Diagnostics Holdings, Inc. offers a range of innovative products and services aimed at revolutionizing the approach towards the detection and management of coronary heart disease (CHD). These include:
- Epi+Gen CHD: This advanced diagnostic solution offers a three-year symptomatic coronary heart disease (CHD) risk assessment test specifically designed to target CHD events, including heart attacks. By integrating the latest advancements in epigenetics, Epi+Gen CHD provides a more dynamic and precise risk evaluation, empowering healthcare providers to adopt more proactive and personalized patient care strategies.
- PrecisionCHD: PrecisionCHD represents a groundbreaking integrated epigenetic-genetic blood test tailored for the early detection of coronary heart disease. The combination of genetic and epigenetic markers in a single test enhances the sensitivity and specificity of CHD detection, facilitating earlier interventions and potentially saving lives. This innovative approach underscores Cardio Diagnostics Holdings, Inc.'s commitment to leveraging the synergy between genetic and epigenetic factors in the battle against cardiovascular diseases.
Contact Information
Address: 400 N Aberdeen St
Phone: 855 226 9991
Website: https://cardiodiagnosticsinc.com
